<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Clin. Invest</journal-id>
<journal-id journal-id-type="publisher-id">J Clin Invest</journal-id>
<journal-title-group>
<journal-title>The Journal of Clinical Investigation</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9738</issn>
<issn pub-type="epub">1558-8238</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30352049</article-id>
<article-id pub-id-type="pmc">6307939</article-id>
<article-id pub-id-type="publisher-id">120816</article-id>
<article-id pub-id-type="doi">10.1172/JCI120816</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Concise Communication</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>Ube3a</italic> reinstatement mitigates epileptogenesis in Angelman syndrome model mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6846-5563</contrib-id>
<name>
<surname>Gu</surname>
<given-names>Bin</given-names>
</name>
<email>bin_gu@med.unc.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carstens</surname>
<given-names>Kelly E.</given-names>
</name>
<email>kcarsten@email.unc.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Judson</surname>
<given-names>Matthew C.</given-names>
</name>
<email>matthew_judson@med.unc.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dalton</surname>
<given-names>Katherine A.</given-names>
</name>
<email>kadalton@live.unc.edu</email>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5797-7515</contrib-id>
<name>
<surname>Rougié</surname>
<given-names>Marie</given-names>
</name>
<email>marie.rougie@gmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Clark</surname>
<given-names>Ellen P.</given-names>
</name>
<email>ellen_clark@med.unc.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4094-8368</contrib-id>
<name>
<surname>Dudek</surname>
<given-names>Serena M.</given-names>
</name>
<email>dudek@niehs.nih.gov</email>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2746-9143</contrib-id>
<name>
<surname>Philpot</surname>
<given-names>Benjamin D.</given-names>
</name>
<email>bphilpot@med.unc.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, North Carolina, USA.</aff>
<aff id="A2"><label>2</label>Neurobiology Laboratory, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina, USA.</aff>
<aff id="A3"><label>3</label>Carolina Institute for Developmental Disabilities,</aff>
<aff id="A4"><label>4</label>Psychology and Neuroscience Program, and</aff>
<aff id="A5"><label>5</label>UNC Neuroscience Center, University of North Carolina, Chapel Hill, North Carolina, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Benjamin D. Philpot, University of North Carolina, 115 Mason Farm Rd., Chapel Hill, North Carolina 27599-7545, USA. Phone: 919.966.0025; Email: <email>bphilpot@med.unc.edu</email>.</corresp>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> The authors have declared that no conflict of interest exists.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2018-11-19T16:00:00-0500" publication-format="electronic">
<day>19</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date date-type="collection" iso-8601-date="2018-11-19T16:00:00-0500" publication-format="electronic">
<day>19</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date date-type="pub" iso-8601-date="2019-01-02T16:00:00-0500" publication-format="print">
<day>2</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>2</day>
<month>4</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 3 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>129</volume>
<issue>1</issue>
<fpage>163</fpage>
<lpage>168</lpage>
<history>
<date date-type="received">
<day>1</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://www.jci.org/articles/view/120816">This article is available online at https://www.jci.org/articles/view/120816</self-uri>
<abstract>
<p>Angelman syndrome (AS) is a neurodevelopmental disorder in which epilepsy is common (~90%) and often refractory to antiepileptics. AS is caused by mutation of the maternal allele encoding the ubiquitin protein ligase E3A (UBE3A), but it is unclear how this genetic insult confers vulnerability to seizure development and progression (i.e., epileptogenesis). Here, we implemented the flurothyl kindling and retest paradigm in AS model mice to assess epileptogenesis and to gain mechanistic insights owed to loss of maternal <italic>Ube3a</italic>. AS model mice kindled similarly to wild-type mice, but they displayed a markedly increased sensitivity to flurothyl-, kainic acid–, and hyperthermia-induced seizures measured a month later during retest. Pathological characterization revealed enhanced deposition of perineuronal nets in the dentate gyrus of the hippocampus of AS mice in the absence of overt neuronal loss or mossy fiber sprouting. This pro-epileptogenic phenotype resulted from <italic>Ube3a</italic> deletion in GABAergic but not glutamatergic neurons, and it was rescued by pancellular reinstatement of <italic>Ube3a</italic> at postnatal day 21 (P21), but not during adulthood. Our results suggest that epileptogenic susceptibility in AS patients is a consequence of the dysfunctional development of GABAergic circuits, which may be amenable to therapies leveraging juvenile reinstatement of <italic>UBE3A</italic>.</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Neuroscience</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Epilepsy</kwd>
<kwd>Neurological disorders</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>NIH</funding-source>
<award-id>ZIAES100221</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>American Epilepsy Society</institution>
<institution-id>https://doi.org/10.13039/100001454</institution-id>
</institution-wrap>
</funding-source>
<award-id>Postdoctoral fellowship</award-id>
</award-group>
<award-group>
<funding-source>NINDS</funding-source>
<award-id>R56NS097831</award-id>
</award-group>
<award-group>
<funding-source>NINDS</funding-source>
<award-id>R01NS085093</award-id>
</award-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Angelman Syndrome Foundation</institution>
<institution-id>https://doi.org/10.13039/100001951</institution-id>
</institution-wrap>
</funding-source>
<award-id>Research grant</award-id>
</award-group>
<award-group>
<funding-source>NICHD</funding-source>
<award-id>R01HD093771</award-id>
</award-group>
<funding-statement>To SMD</funding-statement>
<funding-statement>To BG</funding-statement>
<funding-statement>To BDP</funding-statement>
<funding-statement>To BDP</funding-statement>
<funding-statement>To BDP</funding-statement>
<funding-statement>To BDP</funding-statement>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>